KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Operating Expenses (2017 - 2026)

Amneal Pharmaceuticals has reported Other Operating Expenses over the past 9 years, most recently at $1000.0 for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 100.0% year-over-year to $1000.0; the TTM value through Dec 2025 reached $5.1 million, up 224.45%, while the annual FY2025 figure was $5.2 million, 463.44% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $1000.0 at Amneal Pharmaceuticals, down from $5.1 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $95.8 million in Q4 2024 and troughed at -$94.4 million in Q1 2024.
  • A 5-year average of $1.0 million and a median of $1000.0 in 2025 define the central range for Other Operating Expenses.
  • Biggest five-year swings in Other Operating Expenses: soared 751.26% in 2023 and later tumbled 3742.08% in 2024.
  • Year by year, Other Operating Expenses stood at $19.0 million in 2021, then plummeted by 111.72% to -$2.2 million in 2022, then soared by 751.26% to $14.5 million in 2023, then surged by 561.03% to $95.8 million in 2024, then tumbled by 100.0% to $1000.0 in 2025.
  • Business Quant data shows Other Operating Expenses for AMRX at $1000.0 in Q4 2025, $5.1 million in Q1 2025, and $95.8 million in Q4 2024.